86 related articles for article (PubMed ID: 10600193)
1. The vaccine containing recombinant pertussis toxin induces early and long-lasting protection.
Rappuoli R
Biologicals; 1999 Jun; 27(2):99-102. PubMed ID: 10600193
[TBL] [Abstract][Full Text] [Related]
2. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
3. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.
Petre J; Pizza M; Nencioni L; Podda A; De Magistris MT; Rappuoli R
Dev Biol Stand; 1996; 87():125-34. PubMed ID: 8854009
[TBL] [Abstract][Full Text] [Related]
4. Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
Seubert A; D'Oro U; Scarselli M; Pizza M
Expert Rev Vaccines; 2014 Oct; 13(10):1191-204. PubMed ID: 25183193
[TBL] [Abstract][Full Text] [Related]
5. Bacterial ADP-ribosylating toxins: form, function, and recombinant vaccine development.
Burnette WN
Behring Inst Mitt; 1997 Feb; (98):434-41. PubMed ID: 9382767
[TBL] [Abstract][Full Text] [Related]
6. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
[TBL] [Abstract][Full Text] [Related]
7. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L
Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545
[TBL] [Abstract][Full Text] [Related]
8. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
9. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.
Di Tommaso A; Bartalini M; Peppoloni S; Podda A; Rappuoli R; De Magistris MT
Vaccine; 1997 Aug; 15(11):1218-24. PubMed ID: 9286047
[TBL] [Abstract][Full Text] [Related]
10. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
[TBL] [Abstract][Full Text] [Related]
11. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
Calver GA
Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
[TBL] [Abstract][Full Text] [Related]
12. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Kuno-Sakai H; Kimura M; Watanabe H
Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
[TBL] [Abstract][Full Text] [Related]
13. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test.
Gomez SR; Yuen CT; Asokanathan C; Douglas-Bardsley A; Corbel MJ; Coote JG; Parton R; Xing DK
Vaccine; 2007 Apr; 25(17):3311-8. PubMed ID: 17287049
[TBL] [Abstract][Full Text] [Related]
14. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine.
Loosmore SM; Zealey GR; Boux HA; Cockle SA; Radika K; Fahim RE; Zobrist GJ; Yacoob RK; Chong PC; Yao FL
Infect Immun; 1990 Nov; 58(11):3653-62. PubMed ID: 2228237
[TBL] [Abstract][Full Text] [Related]
15. Mutants of pertussis toxin suitable for vaccine development.
Pizza M; Covacci A; Bartoloni A; Perugini M; Nencioni L; De Magistris MT; Villa L; Nucci D; Manetti R; Bugnoli M
Science; 1989 Oct; 246(4929):497-500. PubMed ID: 2683073
[TBL] [Abstract][Full Text] [Related]
16. Approaches to the control of acellular pertussis vaccines.
Corbel MJ; Xing DK; Bolgiano B; Hockley DJ
Biologicals; 1999 Jun; 27(2):133-41. PubMed ID: 10600202
[TBL] [Abstract][Full Text] [Related]
17. Effect of relevant culture parameters on Pertussis Toxin expression by Bordetella pertussis.
Thalen M; Venema M; van den IJssel J; Berwald L; Beuvery C; Martens D; Tramper J
Biologicals; 2006 Sep; 34(3):213-20. PubMed ID: 16497513
[TBL] [Abstract][Full Text] [Related]
18. Toxicity tests on native and recombinant Bordetella pertussis adenylate cyclase toxin preparations.
Hormozi K; Parton R; Coote J
Dev Biol Stand; 1999; 101():147-54. PubMed ID: 10566788
[TBL] [Abstract][Full Text] [Related]
19. Genetically detoxified pertussis toxin induces superior antigen specific CD4 T cell responses compared to chemically detoxified pertussis toxin.
Surendran N; Pichichero M
Hum Vaccin Immunother; 2019; 15(5):1167-1170. PubMed ID: 30689515
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis of pertussis toxin promoter.
Wo YY; Chiu SC; Lu CH
J Microbiol Immunol Infect; 1999 Sep; 32(3):163-72. PubMed ID: 10637714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
